Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 7/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11507070 | 0.82 | VCAM1 (0.39) | TP53TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL95434 | 0.80 | TP53 (0.48) | TP53TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL27613550 | 0.78 | PTGDR2 (0.40) | TP53TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL6897410 | 0.76 | ALDH1A1 (0.40) | TDP1ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL28759368 | 0.76 | S100A4 (0.38) | TP53TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL27623468 | 0.76 | CYP3A4 (0.52) | TP53TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL5163990 | 0.76 | HSD17B10 (0.50) | TSHRTDP1ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL2490883 | 0.76 | MAPK1 (0.38) | TDP1MAPK1VCAM1 | |
| SCHEMBL21201419 | 0.76 | CYP3A4 (0.46) | TP53ALDH1A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL6212276 | 0.76 | PTGDR2 (0.36) | TDP1ALDH1A1PTGDR2MAPK1VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4399212-A1 | SUBSTITUTED 2,3-DIHYDRO[1,3]THIAZOLO[4,5-B]PYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2024-07-17 | — | — | EP | claimed |
| CN-118159542-A | Substituted 2, 3-dihydro [1,3] thiazolo [4,5-b ] pyridines, salts thereof and their use as herbicidal agents | 拜耳公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2023036707-A1 | SUBSTITUTED 2,3-DIHYDRO[1,3]THIAZOLO[4,5-B]PYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-16 | — | — | WO | claimed |
| CN-111499654-B | Method for synthesizing 3-chloro-thiophene [2, 3-b ] pyridine derivative | 南通诺泰生物医药技术有限公司 | 2022-09-02 | — | — | CN | claimed |
| EP-3672978-B1 | PROCESS FOR MAKING IXAZOMIB AND ITS INTERMEDIATES | SYNTHON BV (NL) | 2021-10-06 | — | — | EP | claimed |
| CN-111499654-A | Method for synthesizing 3-chloro-thiophene [2, 3-b ] pyridine derivative | 南通诺泰生物医药技术有限公司 | 2020-08-07 | — | — | CN | claimed |
| EP-3672978-A1 | PROCESS FOR MAKING IXAZOMIB OR INTERMEDIATES THEREFOR | Synthon B.V. (NL) | 2020-07-01 | — | — | EP | claimed |
| US-20200199159-A1 | PROCESS FOR MAKING IXAZOMIB OR INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2020-06-25 | — | — | US | claimed |
| WO-2019038406-A1 | PROCESS FOR MAKING IXAZOMIB OR INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2019-02-28 | — | — | WO | claimed |
| CN-107311859-A | A kind of efficient chlorobenzoyl chloride chlorination coproduction m-chlorobenzoyl chloride and 2, the method for 5 dichlorobenzoyl chlorides | 江苏万隆化学有限公司 | 2017-11-03 | — | — | CN | claimed |
| US-6150378-A | 1-((1-HALO-SUBSTITUTEDBENZOYLAMINO)-2-PHENYLETHYL)-CARBONYL -CARBONYLAMINO),2-PHENYL OR PYRID-2-YLSULFAMIDO)ETHANE DERIVATIVES; MUSCULAR DYSTROPHY, NEURODEGENERATION, STROKE, ALZHEIMER'S, AMYOTROPHY, MOTOR NEURON DAMAGE, CNS INJURY | CEPHALON, INC. (US) | 2000-11-21 | — | — | US | claimed |
| EP-0983507-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0560268-B1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-01-04 | — | — | EP | claimed |
| WO-1993018003-A1 | SUBSTITUED PIPECOLINIC ACID DERIVATIVES AS HIV PROTEASE INHIBITORS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | claimed |
| EP-0560268-A1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199159-A1 | PROCESS FOR MAKING IXAZOMIB OR INTERMEDIATES THEREFOR | GLP1R, CDK11B, GIPR | TP53 2051/4885TSHR 329/4885TDP1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.